Manitoba Bill 240 proposes broader pharmacist prescribing authority

Manitoba’s Bill 240, The Pharmaceutical Amendment Act, proposes a wider role for pharmacists in treating minor conditions. The private member’s bill was introduced on October 14 and debated at second reading in the Legislative Assembly the following day. It is a proposal—not a change pharmacists can practise under today.

What the bill would change

The bill would amend The Pharmaceutical Act to let a pharmacist prescribe drugs designated in future regulations for specified conditions, subject to restrictions or conditions set by regulation. Its list includes examples such as eczema, cold sores, conjunctivitis, non-chronic headache or diarrhea, heartburn, seasonal allergies, shingles, sore throat, strep throat, vaginal yeast infection and Lyme disease prevention. The bill also allows regulations to add conditions and specify which drugs could be used, in what circumstances, and under what limits.

That structure matters. Bill 240 does not itself establish a final drug list, assessment protocol, training requirement, documentation standard, referral pathway or payment model. Those details would need to be worked out through regulations and applicable professional standards. The bill states that it would come into force 180 days after receiving Royal Assent; the bill text does not show an assent date.

Access goals meet implementation questions

Bill sponsor Kathleen Cook argued in the House that a broader scope could give patients another timely point of care, particularly in rural and northern communities, and make fuller use of pharmacists’ training. The October 15 Hansard also records discussion of how regulations could define eligible drugs and conditions and what clinical standards, documentation, referrals and patient safeguards would be needed. The Legislature’s bill-status sheet, last updated October 15, lists the bill’s first-reading date but no Royal Assent. The bill would come into force only 180 days after any Royal Assent.

Doctors Manitoba’s October 22 response says improved access matters while raising concerns about communication between pharmacies and medical clinics, reliable follow-up and referral when symptoms may signal a more serious condition. It also calls for safeguards against workplace pressures that could undermine patient-centred decisions. These are the medical association’s stated concerns; they are not requirements or findings in the bill itself. The legislative text leaves significant implementation choices to regulations.

For pharmacy teams, the near-term development is the policy debate, not a new prescribing entitlement. Manitoba pharmacists should continue to use only authorities currently in force and should avoid presenting the bill’s proposed list as available services. If legislation advances, the regulations and regulator guidance—not the bill title or a political statement—will determine the actual scope, qualifications, limits and workflows.

Practice guidance for pharmacists

• Continue to follow Manitoba’s current legislation, regulations and College standards. Do not prescribe for the proposed Bill 240 conditions solely on the basis that the bill has been introduced or debated.
• Monitor the Legislature’s bill-status page for the next stage, any amendments, Royal Assent and the commencement date. The bill’s text specifies a 180-day delay after Royal Assent before it would come into force.
• If regulations are introduced, check the exact designated drugs, conditions, patient eligibility, circumstances, restrictions and any training or documentation requirements before planning a service.
• Maintain clear processes under current practice for red-flag symptoms, escalation and referral. A minor-ailment presentation can still require assessment by another clinician.
• When patients ask about the proposal, explain that it is under legislative consideration and that future rules would need to define how any expansion works; do not promise a launch date or coverage for a proposed service.

Bill 240 sets out a possible framework, while the practical boundaries would depend on what legislators and regulators do next. Until then, Manitoba pharmacists’ authority remains the scope already in force.